Intelligence Feed event · Equity · 2026-09-19

    Teva presents real-world data showing UZEDY treatment continuity advantage

    Question

    Teva presents real-world data showing UZEDY treatment continuity advantage

    Direct answer

    Teva released real-world comparative evidence indicating that its long-acting injectable suspension UZEDY delivered higher treatment retention than rival long-acting injectable and oral treatments in schizophrenia and bipolar I disorder. The findings emphasize lower acute healthcare utilization, providing health economics data to support formulary adoption among institutional healthcare payers.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-19
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Teva presents real-world data showing UZEDY treatment continuity advantage”, revision 1, evidence through 2026-09-19. https://marketontology.com/market-events/2026-09-19/teva-presents-real-world-data-showing-uzedy-treatment-continuity-advantage-3eda5a

    EQUITY
    Teva presents real-world data showing UZEDY treatment continuity advantage
    Teva released real-world comparative evidence indicating that its long-acting injectable suspension UZEDY delivered higher treatment retention than rival long-acting injectable and oral treatments in schizophrenia and bipolar I disorder. The findings emphasize lower acute healthcare utilization, providing health economics data to support formulary adoption among institutional healthcare payers.
    TEVA
    Impact
    64
    SEP 19
    SIG
    82%
    TEVA
    Teva presents real-world data showing UZEDY treatment continuity advantage
    Teva released real-world comparative evidence indicating that its long-acting injectable suspension UZEDY delivered higher treatment retention than rival long-acting injectable and oral treatments in schizophrenia and bipolar I disorder. The findings emphasize lower acute healthcare utilization, providing health economics data to support formulary adoption among institutional healthcare payers.
    → Superior clinical adherence and hospitalization reduction data support commercial payer formulary placement and prescription share gains for TEVA.
    Impact
    Teva released real-world comparative evidence indicating that its long-acting injectable suspension UZEDY delivered higher treatment retention than rival long-acting injectable and oral treatments in schizophrenia and bipolar I disorder. The findings emphasize lower acute healthcare utilization, providing health economics data to support formulary adoption among institutional healthcare payers.
    Affected
    TEVA
    Transmission
    Superior clinical adherence and hospitalization reduction data support commercial payer formulary placement and prescription share gains for TEVA.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    TEVAspecialty pharmaceutical formulary adoptionUp1-3mReal-world study establishes treatment continuity superiority and healthcare cost reductions for UZEDY.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month